Cancer treatment research and biotech developments by Syndax Pharmaceuticals

  • Dan Blystone
  • 07.06.2026
Syndax Pharmaceuticals stock drops 3.77% amid National Cancer Survivors Day tweet, Syndax notes
Syndax Pharmaceuticals marked National Cancer Survivors Day as an opportunity to honor cancer survivors and highlight the importance of ongoing care beyond treatment.The company shared the story ...
  • Emilio Ghigini
  • 05.06.2026
Syndax Pharmaceuticals stock nears weekly lows on persistent downside momentum despite ASCO26 involvement
Syndax Pharmaceuticals participated in the 2026 ASCO Annual Meeting.The company stated it joined other industry leaders shaping the future of cancer care. Syndax Pharmaceuticals invited people to ...
  • Andreas Kristo
  • 11.03.2026
Syndax Pharmaceuticals leadership to present at Barclays Global Healthcare Conference
Syndax Pharmaceuticals will participate in the Barclays 28th Annual Global Healthcare Conference, with company leadership scheduled to present at 11:00 a.m. ET on March 12. The session will focus ...
  • Dmytro Kharkov
  • 07.01.2026
Syndax Pharmaceuticals expands orphan drug access via new alliance
Syndax Pharmaceuticals has announced a strategic collaboration with the World Orphan Drug Alliance (WODA) to enhance the availability of Revuforj® (revumenib) through a Managed Access Program. ...
  • Dmytro Kharkov
  • 03.11.2025
Syndax Pharmaceuticals secures 23 ASH25 presentations highlighting research progress
Syndax Pharmaceuticals has announced a significant milestone in its research efforts with the acceptance of 23 abstracts, including six oral presentations, for the upcoming 67th American Society ...